Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Yap TA, et al. Among authors: lim jsj. Cancer Discov. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163. Epub 2020 Jun 12. Cancer Discov. 2020. PMID: 32532747 Free PMC article. Clinical Trial.
Emerging biomarkers for PD-1 pathway cancer therapy.
Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA. Lim JS, et al. Biomark Med. 2017 Jan;11(1):53-67. doi: 10.2217/bmm-2016-0228. Epub 2016 Dec 12. Biomark Med. 2017. PMID: 27936870 Review.
Circulating tumor DNA-From bench to bedside.
Lim JSJ, Janku F, Yap TA. Lim JSJ, et al. Curr Probl Cancer. 2017 May-Jun;41(3):212-221. doi: 10.1016/j.currproblcancer.2017.02.005. Epub 2017 Mar 1. Curr Probl Cancer. 2017. PMID: 28416241
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Pascual J, Lim JSJ, Macpherson IR, Armstrong AC, Ring A, Okines AFC, Cutts RJ, Herrera-Abreu MT, Garcia-Murillas I, Pearson A, Hrebien S, Gevensleben H, Proszek PZ, Hubank M, Hills M, King J, Parmar M, Prout T, Finneran L, Malia J, Swales KE, Ruddle R, Raynaud FI, Turner A, Hall E, Yap TA, Lopez JS, Turner NC. Pascual J, et al. Among authors: lim jsj. Cancer Discov. 2021 Jan;11(1):92-107. doi: 10.1158/2159-8290.CD-20-0553. Epub 2020 Sep 21. Cancer Discov. 2021. PMID: 32958578 Free article.
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
Lee SC, Shimasaki N, Lim JSJ, Wong A, Yadav K, Yong WP, Tan LK, Koh LP, Poon MLM, Tan SH, Ow SGW, Bharwani L, Yap YS, Foo MZQ, Coustan-Smith E, Sundar R, Tan HL, Chong WQ, Kumarakulasinghe NB, Lieow JLM, Koe PJX, Goh BC, Campana D. Lee SC, et al. Among authors: lim jsj. Clin Cancer Res. 2020 Sep 1;26(17):4494-4502. doi: 10.1158/1078-0432.CCR-20-0768. Epub 2020 Jun 10. Clin Cancer Res. 2020. PMID: 32522887 Clinical Trial.
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.
Lim JSJ, Wong ALA, Ow SGW, Ngoi NYL, Chan GHJ, Ang YLE, Chong WQ, Lim SE, Lim YW, Lee M, Choo JRE, Tan HL, Yong WP, Soo RA, Tan DSP, Chee CE, Sundar R, Yadav K, Jain S, Wang L, Tai BC, Goh BC, Lee SC. Lim JSJ, et al. Among authors: lim se, lim yw. Clin Cancer Res. 2022 Jun 1;28(11):2248-2256. doi: 10.1158/1078-0432.CCR-21-4179. Clin Cancer Res. 2022. PMID: 35363275 Clinical Trial.
42 results